A
Overview
Ametris partners with life sciences groups to turn real-world patient data into evidence that informs clinical trials. Its end-to-end digital health technology platform combines wearable sensors, scientific expertise, and regulatory-aligned analytics to support a trial from design through submission. Unlike using a collection of separate tools, Ametris provides a single, coordinated solution for data collection, analysis, and regulatory reporting. Its goal is to improve science and patient lives by delivering clear, actionable evidence that helps clinical development move faster and with less risk.
Work here?Claim your company
Simplify's take
What believers are saying
- Signant announced acquisition on May 14, 2026, validating Ametris' strategic value.
- Ametris launched partnerships with Signant and Kayentis in 2026, widening distribution.
- Biofourmis Connect made the platform device-agnostic, strengthening trials with mixed hardware.
What critics are saying
- Signant integration can bury Ametris under a broader platform by 2027.
- Clinical-trial buyers can switch vendors fast if unified analytics disappoint.
- No disclosed deal terms leave valuation discipline and post-close retention risk opaque.
What makes Ametris unique
- Ametris pairs wearable-derived digital endpoints with Signant's eCOA in one workflow.
- LEAP received FDA 510(k) clearance in October 2023 for biometric sensing.
- ARCHIMED says Ametris serves top 25 pharma across 150-plus countries.
Help us improve and share your feedback! Did you find this helpful?